Komori
Share Issuance and Disposal7776CellSeed Inc.Electric Appliances & Precision Instruments

Notice Regarding the Completion of the Allocation of Funds Raised Through the Exercise of the 24th Series of Stock Acquisition Rights with an Exercise Price Adjustment Clause

The funds raised through the exercise of the 24th Series of Stock Acquisition Rights have been fully allocated, comprising ¥1,387 million for research and development and ¥606 million for working capital, leaving no unallocated amount.

Worth reading
80Important
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1993
Millions of yen
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Report on the Completion of the Allocation of Funds Raised Through the Exercise of Stock Acquisition Rights with an Exercise Price Adjustment Clause

Amount of funds to be raised

Total funds raised: ¥1,993 million; estimated net proceeds after expenses: Not disclosed

Specific use of funds
R&D FundingAmount ¥1,387 million / Scheduled timing of expenditures September 2026
Working capitalAmount ¥606 million / Scheduled timing of expenditures September 2026
Terms of the stock acquisition rights
Exercise price
Only the inclusion of an exercise price adjustment clause is stated; the initial exercise price and adjustment floor: Not disclosed
Most recent equity financing
Timing 5 June 2023 / Type Issuance of the 24th Series of Stock Acquisition Rights with an Exercise Price Adjustment Clause / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReport on the Completion of the Allocation of Funds Raised Through the Exercise of Stock Acquisition Rights with an Exercise Price Adjustment Clause
Amount of funds to be raisedTotal funds raised: ¥1,993 million; estimated net proceeds after expenses: Not disclosed
Specific use of fundsDetails R&D Funding / Amount ¥1,387 million / Scheduled timing of expenditures September 2026, Details Working capital / Amount ¥606 million / Scheduled timing of expenditures September 2026
Exercise priceOnly the inclusion of an exercise price adjustment clause is stated; the initial exercise price and adjustment floor: Not disclosed
Most recent equity financingTiming 5 June 2023 / Type Issuance of the 24th Series of Stock Acquisition Rights with an Exercise Price Adjustment Clause / Amount Not disclosed
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

A disclosure dated 20 November 2025 stated that the Company would make a timely disclosure as soon as the allocation of the funds was completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Completion of the Allocation of Funds Raised Through the Exercise of the 24th Series of Stock Acquisition Rights with an Exercise Price Adjustment Clause | CellSeed Inc. (7776) timely disclosure | Komori